CDK versus GSK-3 inhibition: a purple haze no longer?
The ubiquitous ATP binding site offers a global target for protein kinase inhibitors. The corollary is that molecular selectivity with such agents may be difficult to achieve and ascertain. A relevant example is discussed in terms of design and biomedical rationale.